Changes in gene expression of neo-squamous mucosa after endoscopic treatment for dysplastic Barrett’s esophagus and intramucosal adenocarcinoma

Background Endoscopic therapy, including by radiofrequency ablation (RFA) or endoscopic mucosal resection (EMR), is first line treatment for Barrett’s esophagus (BE) with high-grade dysplasia (HGD) or intramucosal cancer (IMC) and may be appropriate for some patients with low-grade dysplasia (LGD). Objective The purpose of this study was to investigate the molecular effects of endotherapy. Methods mRNA expression of 16 genes significantly associated with different BE stages was measured in paired pre-treatment BE tissues and post-treatment neo-squamous biopsies from 36 patients treated by RFA (19 patients, 3 IMC, 4 HGD, 12 LGD) or EMR (17 patients, 4 IMC, 13 HGD). EMR was performed prior to RFA in eight patients. Normal squamous esophageal tissues were from 20 control individuals. Results Endoscopic therapy resulted in significant change towards the normal squamous expression profile for all genes. The neo-squamous expression profile was significantly different to the normal control profile for 11 of 16 genes. Conclusion Endotherapy results in marked changes in mRNA expression, with replacement of the disordered BE dysplasia or IMC profile with a more “normal” profile. The neo-squamous mucosa was significantly different to the normal control squamous mucosa for most genes. The significance of this finding is uncertain but it may support continued endoscopic surveillance after successful endotherapy.

[1]  D. Whiteman,et al.  Long-term outcomes of a primary complete endoscopic resection strategy for short-segment Barrett's esophagus with high-grade dysplasia and/or early esophageal adenocarcinoma. , 2016, Gastrointestinal endoscopy.

[2]  Nicholas J Shaheen,et al.  ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus , 2016, The American Journal of Gastroenterology.

[3]  A. Chak,et al.  Advances in the management of Barrett’s esophagus and early esophageal adenocarcinoma , 2015, Gastroenterology report.

[4]  P. Malfertheiner,et al.  BOB CAT: a Large-Scale Review and Delphi Consensus for Management of Barrett’s Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia , 2015, The American Journal of Gastroenterology.

[5]  J. Emery,et al.  Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma , 2015, Journal of gastroenterology and hepatology.

[6]  Alexander Meining,et al.  Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II) , 2015, Gut.

[7]  Kenneth K Wang,et al.  Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers. , 2014, Gastrointestinal endoscopy.

[8]  J. Tijssen,et al.  Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. , 2014, JAMA.

[9]  L. Gossner,et al.  Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. , 2014, Gastroenterology.

[10]  Rebecca C Fitzgerald,et al.  British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus , 2013, Gut.

[11]  G. Ginsberg,et al.  Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. , 2013, Gastroenterology.

[12]  E. Schoon,et al.  Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. , 2013, Gastroenterology.

[13]  A. Meining,et al.  Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett’s esophagus with early neoplasia: a prospective multicenter study , 2013, Endoscopy.

[14]  N. Shaheen,et al.  Intestinal Metaplasia Recurs Infrequently in Patients Successfully Treated for Barrett's Esophagus With Radiofrequency Ablation , 2013, The American Journal of Gastroenterology.

[15]  J. Pandolfino,et al.  Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation. , 2012, Gastroenterology.

[16]  D. Hussey,et al.  Molecular biomarkers and ablative therapies for Barrett’s esophagus , 2012, Expert review of gastroenterology & hepatology.

[17]  Kenneth K Wang,et al.  Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus. , 2012, Gastroenterology.

[18]  J. Akiyama,et al.  Effective Intra-Esophageal Acid Control Is Associated with Improved Radiofrequency Ablation Outcomes in Barrett’s Esophagus , 2012, Digestive Diseases and Sciences.

[19]  S. Komanduri,et al.  Radiofrequency Ablation for Dysplasia in Barrett’s Esophagus Restores β-Catenin Activation Within Esophageal Progenitor Cells , 2012, Digestive Diseases and Sciences.

[20]  Hiroshi Mashimo,et al.  Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. , 2011, Gastroenterology.

[21]  C. Lightdale,et al.  Detection of Intestinal Metaplasia After Successful Eradication of Barrett’s Esophagus with Radiofrequency Ablation , 2011, Digestive Diseases and Sciences.

[22]  S. Pritchard,et al.  Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett’s esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies , 2011, Surgical Endoscopy.

[23]  B. Overholt,et al.  Biopsy depth after radiofrequency ablation of dysplastic Barrett's esophagus. , 2010, Gastrointestinal endoscopy.

[24]  N. Hayward,et al.  Gene expression alterations in formalin-fixed, paraffin-embedded Barrett esophagus and esophageal adenocarcinoma tissues. , 2010, Cancer biology & therapy.

[25]  M. Bourke,et al.  Endoscopic Resection for Barrett's High-Grade Dysplasia and Early Esophageal Adenocarcinoma: An Essential Staging Procedure With Long-Term Therapeutic Benefit , 2010, The American Journal of Gastroenterology.

[26]  M. Vieth,et al.  Properties of the Neosquamous Epithelium After Radiofrequency Ablation of Barrett's Esophagus Containing Neoplasia , 2009, The American Journal of Gastroenterology.

[27]  M. Michael,et al.  MicroRNA-143 and -205 Expression in Neosquamous Esophageal Epithelium Following Argon Plasma Ablation of Barrett’s Esophagus , 2009, Journal of Gastrointestinal Surgery.

[28]  A. Rastogi,et al.  Esophageal Adenocarcinoma in Barrett's Esophagus After Endoscopic Ablative Therapy: A Meta-Analysis and Systematic Review , 2009, The American Journal of Gastroenterology.

[29]  A. Zinsmeister,et al.  Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. , 2008, Gastroenterology.

[30]  E. Kuipers,et al.  Genomic analysis of Barrett's esophagus after ablative therapy: Persistence of genetic alterations at tumor suppressor loci , 2006, International journal of cancer.

[31]  P. Marjoram,et al.  The Molecular Signature of Normal Squamous Esophageal Epithelium Identifies the Presence of a Field Effect and Can Discriminate between Patients with Barrett's Esophagus and Patients with Barrett's-Associated Adenocarcinoma , 2005, Cancer Epidemiology Biomarkers & Prevention.

[32]  E. Kuipers,et al.  Molecular evaluation of ablative therapy of Barrett's oesophagus , 2005, The Journal of pathology.

[33]  Paul Marjoram,et al.  A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus , 2004, Oncogene.

[34]  S. Groshen,et al.  Retinoic acid receptor-α messenger RNA expression is increased and retinoic acid receptor-γ expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence , 2001 .

[35]  S. Groshen,et al.  Retinoic acid receptor-alpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence. , 2001, Surgery.

[36]  N. Buttar,et al.  Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. , 2000, Gastroenterology.